<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
    <channel>
        <title>Dermatologic Clinics via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Dermatologic Clinics' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Dermatologic+Clinics&t=Dermatologic+Clinics&s=Search&f=source]]></link>
        <lastBuildDate>Wed, 08 Feb 2012 13:12:29 +0100</lastBuildDate>
        <item>
            <title>Index</title>
            <link>http://www.medworm.com/index.php?rid=5647959&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863512000198%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647959</comments>
            <pubDate>Thu, 02 Feb 2012 17:38:41 +0100</pubDate>
            <guid isPermaLink="false">5647959</guid>        </item>
        <item>
            <title>Clinical Meaning in Skin-specific Quality of Life Instruments: A Comparison of the Dermatology Life Quality Index and Skindex Banding Systems</title>
            <link>http://www.medworm.com/index.php?rid=5647957&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511002051%2Fabstract%3Frss%3Dyes</link>
            <description>This article focuses on the anchor-based banding approach and reviews methods to assign clinical meaning to QOL measures, specifically the Dermatology Life Quality Index (DLQI) and Skindex. This article also includes pilot data that compares the DLQI and Skindex using these previously validated banding systems. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647957</comments>
            <pubDate>Thu, 02 Feb 2012 17:38:41 +0100</pubDate>
            <guid isPermaLink="false">5647957</guid>        </item>
        <item>
            <title>Quality-of-Life Instruments: Evaluation of the Impact of Psoriasis on Patients</title>
            <link>http://www.medworm.com/index.php?rid=5647952&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511002014%2Fabstract%3Frss%3Dyes</link>
            <description>The negative impact of psoriasis on a patient's quality of life (QoL) is well documented in the literature. Patients often suffer poor self-esteem, difficulties in social interactions, and significant psychological distress. It is, therefore, critically important that a clinician evaluate the extent to which the disease impacts a patient's QoL. This chapter reviews several validated and reliable generic, dermatology-specific, and disease-specific QoL instruments useful in measuring the impact of psoriasis on patient's QoL. These QoL instruments can be especially helpful in identifying those patients who would most benefit from systemic or biologic therapy. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647952</comments>
            <pubDate>Thu, 02 Feb 2012 17:38:40 +0100</pubDate>
            <guid isPermaLink="false">5647952</guid>        </item>
        <item>
            <title>Melasma Quality of Life Measures</title>
            <link>http://www.medworm.com/index.php?rid=5647951&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351100204X%2Fabstract%3Frss%3Dyes</link>
            <description>This article addresses these methods, which could be useful to those desiring to develop the MELASQOL in other languages. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647951</comments>
            <pubDate>Thu, 02 Feb 2012 17:38:40 +0100</pubDate>
            <guid isPermaLink="false">5647951</guid>        </item>
        <item>
            <title>Health-Related Quality of Life in Dermatology: Introduction and Overview</title>
            <link>http://www.medworm.com/index.php?rid=5647944&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511002129%2Fabstract%3Frss%3Dyes</link>
            <description>This article introduces a compendium of articles that address HRQoL in dermatology across a spectrum of diseases and ways that HRQoL can be incorporated in the clinical and research settings. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647944</comments>
            <pubDate>Thu, 02 Feb 2012 17:38:40 +0100</pubDate>
            <guid isPermaLink="false">5647944</guid>        </item>
        <item>
            <title>Forthcoming Issues</title>
            <link>http://www.medworm.com/index.php?rid=5647942&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863512000186%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647942</comments>
            <pubDate>Thu, 02 Feb 2012 17:38:40 +0100</pubDate>
            <guid isPermaLink="false">5647942</guid>        </item>
        <item>
            <title>Contents</title>
            <link>http://www.medworm.com/index.php?rid=5647941&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863512000174%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647941</comments>
            <pubDate>Thu, 02 Feb 2012 17:38:40 +0100</pubDate>
            <guid isPermaLink="false">5647941</guid>        </item>
        <item>
            <title>Contributors</title>
            <link>http://www.medworm.com/index.php?rid=5647940&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863512000162%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647940</comments>
            <pubDate>Thu, 02 Feb 2012 17:38:40 +0100</pubDate>
            <guid isPermaLink="false">5647940</guid>        </item>
        <item>
            <title>Overview of Health Status Quality-of-Life Measures</title>
            <link>http://www.medworm.com/index.php?rid=5647945&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511002026%2Fabstract%3Frss%3Dyes</link>
            <description>The concept of quality of life (QOL) is becoming increasingly important in medicine, particularly in dermatology where many cutaneous diseases have the potential to affect the quality rather than the length of life. There is increasing interest in devising methodology to accurately measure the impact of disease on QOL for use in clinical practice, research studies, and economic analyses. The question of which dermatologic QOL instruments to choose inevitably arises. The aim of this article is to familiarize readers with health status measures and to review their use in dermatology. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647945</comments>
            <pubDate>Fri, 06 Jan 2012 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647945</guid>        </item>
        <item>
            <title>Preference-Based Measures in Dermatology: An Overview of Utilities and Willingness to Pay</title>
            <link>http://www.medworm.com/index.php?rid=5647946&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511002130%2Fabstract%3Frss%3Dyes</link>
            <description>In this overview of preference-based measures, utilities and willingness to pay (WTP) are discussed as measures relevant to dermatology for capturing the burden of skin diseases. An overview is provided of the concepts of utilities and WTP and their importance in decision making. Specific examples of elicitation methods for capturing utility and WTP measures are provided. Prior studies exploring utilities and WTP in dermatology are reviewed. Each of these measures has limitations and likely varying relevance to specific dermatologic diseases and to specific individuals. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647946</comments>
            <pubDate>Mon, 26 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647946</guid>        </item>
        <item>
            <title>Future Directions in Dermatology Quality of Life Measures</title>
            <link>http://www.medworm.com/index.php?rid=5647958&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511002002%2Fabstract%3Frss%3Dyes</link>
            <description>Within the last few decades, outcomes research, and in particular quality of life (QoL) outcomes research, has become integrated into clinical and research practices. QoL outcomes are important to dermatology, because many diseases carry significant psychosocial burdens and morbidity from appearance and symptoms with few cases of mortality. In this article, the authors discuss the future directions in QoL. Important areas are the determination, clinical significance and interpretation of measured QoL values. Additionally, the development of proxies for preference-based QoL measures and modules for health status QoL measures are discussed. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647958</comments>
            <pubDate>Fri, 23 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647958</guid>        </item>
        <item>
            <title>Health-Related Quality of Life in Patients with Melanoma: Overview of Instruments and Outcomes</title>
            <link>http://www.medworm.com/index.php?rid=5647949&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511002063%2Fabstract%3Frss%3Dyes</link>
            <description>The increasing public health burden of melanoma warrants evaluation of quality-of-life outcomes and the instruments most commonly used to measure quality of life in patients with melanoma. A review of the published literature focusing on quality-of-life outcomes in melanoma patients was performed to appraise the instruments used for assessment and the significant findings. In general, generic instruments continue to be most commonly used in the evaluation of quality of life despite the lack of responsiveness to changes in quality of life in subsets of patients. Cancer-specific and melanoma-specific instruments may be more suited for longitudinal clinical assessments. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647949</comments>
            <pubDate>Fri, 23 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647949</guid>        </item>
        <item>
            <title>A Review of the Use of the Dermatology Life Quality Index as a Criterion in Clinical Guidelines and Health Technology Assessments in Psoriasis and Chronic Hand Eczema</title>
            <link>http://www.medworm.com/index.php?rid=5647948&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001975%2Fabstract%3Frss%3Dyes</link>
            <description>The Dermatology Life Quality Index (DLQI) is an easy and practical way of quantifying the impact of skin disease. The role of DLQI in treatment guidelines and its emergence as an eligibility and response criterion in health technology appraisal are discussed. This review analyzes the current available literature on the clinical use of the DLQI, with particular reference to its relationship with disease severity and as a criterion in the assessment of health technology. The need for future studies of chronic hand eczema to incorporate DLQI to document quality-of-life outcomes with new treatments is also discussed. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647948</comments>
            <pubDate>Fri, 23 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647948</guid>        </item>
        <item>
            <title>Preface</title>
            <link>http://www.medworm.com/index.php?rid=5647943&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511002117%2Fabstract%3Frss%3Dyes</link>
            <description>Health-related quality of life (HRQoL) is increasingly being recognized as an important parameter to consider in research as well as in patient care. In fact, the Healthy People 2020 initiative, developed by lead federal agencies, such as the Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, National Institutes of Health, and Food and Drug Administration, to name a few, has named “health-related quality of life and well-being” as a new topic area for this decade as a high-priority national health objective. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647943</comments>
            <pubDate>Fri, 23 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647943</guid>        </item>
        <item>
            <title>Health-Related Quality-of-Life Assessment in Dermatologic Practice: Relevance and Application</title>
            <link>http://www.medworm.com/index.php?rid=5647956&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001999%2Fabstract%3Frss%3Dyes</link>
            <description>Health-related quality of life (HRQoL) is gradually becoming a standard outcome in clinical research and health care management. Nevertheless, application in dermatologic practice is not customary and many practical and attitudinal barriers need to be overcome. To contribute to the discussion on and the implementation of HRQoL assessment in routine dermatologic practice, this article describes (1) why HRQoL assessment is relevant for dermatologic practice, (2) which patients would benefit most from routine HRQoL assessment, and (3) how HRQoL assessment can be applied in clinical practice. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647956</comments>
            <pubDate>Thu, 22 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647956</guid>        </item>
        <item>
            <title>Pruritus</title>
            <link>http://www.medworm.com/index.php?rid=5647955&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511002099%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews the instruments that have been developed and used in pruritus and also reviews the literature regarding the impact of pruritus on QoL. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647955</comments>
            <pubDate>Thu, 22 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647955</guid>        </item>
        <item>
            <title>Quality-of-Life Measurement in Blistering Diseases</title>
            <link>http://www.medworm.com/index.php?rid=5647954&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511002038%2Fabstract%3Frss%3Dyes</link>
            <description>Both congenital and acquired bullous dermatoses have the potential to impose a significant burden of disease, and the impact exerted on the quality of life (QOL) of patients is often multifaceted. The qualitative and quantitative studies reviewing QOL in patients with bullous dermatoses have all reported a significant decrease in QOL scores compared with the greater population using a range of patient-based measures. Formal evaluation of QOL in the setting of bullous dermatoses facilitates the assessment of disease severity and mapping of disease trajectory and can capture outcomes of therapeutic intervention relevant to the patient. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647954</comments>
            <pubDate>Thu, 22 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647954</guid>        </item>
        <item>
            <title>The Skindex Instruments to Measure the Effects of Skin Disease on Quality of Life</title>
            <link>http://www.medworm.com/index.php?rid=5647947&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001987%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews the development of both versions of Skindex, discusses their measurement properties and interpretability, and gives examples of how they have been used and adapted for dermatologic research internationally. Studies of quality of life in patients with nonmelanoma skin cancer are described to illustrate the use of Skindex to understand quality of life and to compare effectiveness of different treatments for this highly prevalent condition. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647947</comments>
            <pubDate>Thu, 22 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647947</guid>        </item>
        <item>
            <title>Quality of Life Measures for Acne Patients</title>
            <link>http://www.medworm.com/index.php?rid=5647953&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001963%2Fabstract%3Frss%3Dyes</link>
            <description>Acne vulgaris affects most adolescents and two-thirds of adults and is associated with substantial psychosocial burden. Health-related quality of life (HRQOL) for patients with acne is an important factor of patient care, and several dermatologic and acne-specific measures have been created to assist in acne research, management, and care. This review describes several skin disease and acne-specific HRQOL measures and their applications in clinical care or research. The ideal HRQOL measure for the management of patients with acne is a concise questionnaire that places minimal burden on respondents and allows physicians to track improvement in HRQOL with successful treatment. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647953</comments>
            <pubDate>Mon, 19 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647953</guid>        </item>
        <item>
            <title>Quality-of-Life Issues in Vitiligo</title>
            <link>http://www.medworm.com/index.php?rid=5647950&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511002105%2Fabstract%3Frss%3Dyes</link>
            <description>Vitiligo, an acquired disease of depigmentation, affects millions worldwide. The psychosocial and health-related quality of life (HRQL) impact of the disease varies based on several parameters, including country of origin, skin type, gender, age, marital status, and involved body site. Many instruments, both dermatology specific and dermatology nonspecific, have been used to measure HRQL. Assessing HRQL in vitiligo is an important part of disease management. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5647950</comments>
            <pubDate>Mon, 19 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5647950</guid>        </item>
        <item>
            <title>Index</title>
            <link>http://www.medworm.com/index.php?rid=5457866&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001872%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457866</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457866</guid>        </item>
        <item>
            <title>Conclusions and Recommendations: United States Dermatologic Health Care Need Assessment</title>
            <link>http://www.medworm.com/index.php?rid=5457865&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001756%2Fabstract%3Frss%3Dyes</link>
            <description>This United States skin disease health care needs assessment (HCNA) focuses on the most common and severe skin conditions. The purpose of this article is to highlight these skin conditions in a concise manner for efficient use by policy makers. Brief summaries of each article in this issue of Dermatologic Clinics are provided along with recommendations for better addressing dermatologic care needs. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457865</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457865</guid>        </item>
        <item>
            <title>Needs Assessment for Mohs Micrographic Surgery</title>
            <link>http://www.medworm.com/index.php?rid=5457863&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351100146X%2Fabstract%3Frss%3Dyes</link>
            <description>Mohs micrographic surgery (MMS) is a unique technique that can offer the highest cure rates and maximum tissue conservation in the management of specific primary and recurrent skin cancers. However, there are many areas of controversy that surround MMS, including appropriate indications for its use, technical quandaries, and outcomes. Recent efforts in these areas need to be assessed to identify research gaps in MMS to help fuel further work. The usefulness of MMS and its methods for delivery need more stringent, evidence-based, rigorous study. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457863</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457863</guid>        </item>
        <item>
            <title>Needs Assessment for General Dermatologic Surgery</title>
            <link>http://www.medworm.com/index.php?rid=5457862&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001471%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews current recommendations, strength of evidence, and areas in need of further research in the surgical treatment of melanoma and nonmelanoma skin cancers, as well as other select cutaneous neoplasms. Cryosurgery, electrosurgery, photodynamic therapy, and surgical excision are discussed. Local anesthesia, suturing technique, postsurgical dressings, and optimization of scarring are briefly reviewed. In general, large, high-quality, randomized controlled trials on which to base recommendations are lacking. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457862</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457862</guid>        </item>
        <item>
            <title>US Skin Disease Assessment: Ulcer and Wound Care</title>
            <link>http://www.medworm.com/index.php?rid=5457858&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001410%2Fabstract%3Frss%3Dyes</link>
            <description>Chronic ulcers are a growing cause of patient morbidity and contribute significantly to the cost of health care in the United States. The most common etiologies of chronic ulcers include venous leg ulcers (VLUs), pressure ulcers (PrUs), diabetic neuropathic foot ulcers (DFUs), and leg ulcers of arterial insufficiency. Chronic wounds account for an estimated $6 to $15 billion annually in US health care costs; however, it is difficult to get accurate measurements on this, because these patients are often seen in a variety of settings or simply fail to access the health care system. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457858</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457858</guid>        </item>
        <item>
            <title>Contact Dermatitis in the United States: Epidemiology, Economic Impact, and Workplace Prevention</title>
            <link>http://www.medworm.com/index.php?rid=5457856&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001409%2Fabstract%3Frss%3Dyes</link>
            <description>This article provides a definition of contact dermatitis and its associated risk factors. The authors discuss the epidemiology of occupational contact dermatitis including its incidence and prevalence, and describe how estimates are calculated in the United States. The burden of disease on the individual, and its economic impact and cost to society, are also elucidated. A review of preventive measures to help reduce contact dermatitis in the workplace and an additional section on patch testing concludes the article. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457856</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457856</guid>        </item>
        <item>
            <title>Health Outcomes in Atopic Dermatitis</title>
            <link>http://www.medworm.com/index.php?rid=5457855&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001434%2Fabstract%3Frss%3Dyes</link>
            <description>Atopic dermatitis is a chronic inflammatory skin disease that disrupts the daily work and social lives of patients. Treatment of atopic dermatitis makes use of a variety of therapies, from medications to nutritional supplements to psychotherapy. Health outcomes research evaluates the efficacy, safety, and impact on health-related quality of life of these therapies. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457855</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457855</guid>        </item>
        <item>
            <title>Dermatologic Health Disparities</title>
            <link>http://www.medworm.com/index.php?rid=5457853&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001380%2Fabstract%3Frss%3Dyes</link>
            <description>Although significant data highlight the extent of health disparities, data regarding dermatologic health disparities are limited. Ethnic minorities, people of low socioeconomic status, the less educated, elderly, and uninsured have poorer melanoma and nonmelanoma skin cancer outcomes. Atopic dermatitis is more prevalent among ethnic minorities, but whether morbidity is also increased in these populations is unclear. Given the current dermatology workforce shortage, increased patient load from health care reform may have an adverse effect on access to dermatologic care. Additional concerns include status of dermatologic training, insufficient research involving ethnic minorities, and lack of investigation of dermatologic health disparities. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457853</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457853</guid>        </item>
        <item>
            <title>Models of Care and Organization of Services</title>
            <link>http://www.medworm.com/index.php?rid=5457852&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351100177X%2Fabstract%3Frss%3Dyes</link>
            <description>This article examines the overall organization of services and delivery of health care in the United States. Health maintenance organization, fee-for-service, preferred provider organizations, and the Veterans Health Administration are discussed, with a focus on structure, outcomes, and areas for improvement. An overview of wait times, malpractice, telemedicine, and the growing population of physician extenders in dermatology is also provided. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457852</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457852</guid>        </item>
        <item>
            <title>Services Available and Their Effectiveness</title>
            <link>http://www.medworm.com/index.php?rid=5457851&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001379%2Fabstract%3Frss%3Dyes</link>
            <description>This article describes the range of services available for patients with skin disease in the United States. Within the structure of health care systems, 4 levels of care are characterized and discussed: self-care and management, generalist care, specialist care, and subspecialist care. Within each level, this article discusses the profiles of individuals involved in delivering medical care, the location or setting in which these services are provided, the capacity and specific activities of care providers, and current literature on the efficacy of these different levels of care. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457851</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457851</guid>        </item>
        <item>
            <title>The Burden of Skin Disease in the United States and Canada</title>
            <link>http://www.medworm.com/index.php?rid=5457850&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001768%2Fabstract%3Frss%3Dyes</link>
            <description>The burden of skin disease is a crucial indicator of the impact of skin disease in the general population. Despite many documented attempts in the literature to quantify independent parameters of skin disease burden, strides towards more comprehensive estimations have mainly arisen in the last decade. Utilizing the World Health Organization breakdown of disease burden, the literature was surveyed and summarized in respect to the classification, epidemiology, quality of life, and costs associated with skin disease. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457850</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457850</guid>        </item>
        <item>
            <title>Introduction: US Dermatologic Health Care Needs Assessment</title>
            <link>http://www.medworm.com/index.php?rid=5457849&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001744%2Fabstract%3Frss%3Dyes</link>
            <description>The health care needs assessment (HCNA) addressed in this issue of Dermatologic Clinics is designed to aid practitioners and policy makers by providing current, evidence-based research that can be used to guide United States' dermatologic care. The topics covered in this skin disease HCNA include those that are considered common dermatology care needs in society and those severe enough to create a burden on the medical system. Disease discussions address epidemiology, costs to society and patients, prevention, treatment, gaps in management, and future recommendations. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457849</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457849</guid>        </item>
        <item>
            <title>Forthcoming Issues</title>
            <link>http://www.medworm.com/index.php?rid=5457846&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001860%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457846</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457846</guid>        </item>
        <item>
            <title>Contents</title>
            <link>http://www.medworm.com/index.php?rid=5457845&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001859%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457845</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457845</guid>        </item>
        <item>
            <title>Contributors</title>
            <link>http://www.medworm.com/index.php?rid=5457844&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001847%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457844</comments>
            <pubDate>Thu, 01 Dec 2011 06:37:24 +0100</pubDate>
            <guid isPermaLink="false">5457844</guid>        </item>
        <item>
            <title>Needs Assessment for Cosmetic Dermatologic Surgery</title>
            <link>http://www.medworm.com/index.php?rid=5457864&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001458%2Fabstract%3Frss%3Dyes</link>
            <description>Cosmetic procedures have been an integral part of dermatologic surgery for over half a century, with a more recent proliferation of devices to improve skin color and texture and modify subcutaneous fat. Overall, cosmetic dermatologic procedures are extremely safe. However, detailed information about safety and effectiveness, and especially comparative effectiveness, is not available for many procedures. There are few randomized control trials of comparative effectiveness of different procedures for similar indications. Key comparative effectiveness studies are briefly reviewed, and areas of substantial deficiency in such research are highlighted. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457864</comments>
            <pubDate>Mon, 24 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457864</guid>        </item>
        <item>
            <title>Infectious Skin Diseases: A Review and Needs Assessment</title>
            <link>http://www.medworm.com/index.php?rid=5457861&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001392%2Fabstract%3Frss%3Dyes</link>
            <description>This article discusses common bacterial, fungal, and viral skin infections with an emphasis on cellulitis, dermatophyte infections, and herpes simplex viral infections. Disease pathogenesis, treatment, and cost of treatment are addressed with an emphasis on therapeutic needs and future research directions. Common priorities for all infectious skin disease categories include increased disease surveillance, study of existing treatments, and efforts in drug development. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457861</comments>
            <pubDate>Mon, 24 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457861</guid>        </item>
        <item>
            <title>Nonmelanoma Skin Cancer</title>
            <link>http://www.medworm.com/index.php?rid=5457860&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001446%2Fabstract%3Frss%3Dyes</link>
            <description>This article highlights these areas of clinical and research need. The article focuses on the recent epidemiologic trends as well as health outcomes of NMSCs in the United States. In addition, current national guidelines, available treatments and care pathways, and clinical trials are discussed. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457860</comments>
            <pubDate>Mon, 24 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457860</guid>        </item>
        <item>
            <title>Acne Vulgaris: Pathogenesis, Treatment, and Needs Assessment</title>
            <link>http://www.medworm.com/index.php?rid=5457857&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001732%2Fabstract%3Frss%3Dyes</link>
            <description>This article discusses the epidemiology, pathogenesis, and treatment of acne vulgaris. The burden of disease in the United States and future directions in the management of acne are also addressed. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457857</comments>
            <pubDate>Mon, 24 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457857</guid>        </item>
        <item>
            <title>Preface</title>
            <link>http://www.medworm.com/index.php?rid=5457847&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001781%2Fabstract%3Frss%3Dyes</link>
            <description>This edition of the Dermatologic Clinics takes a stab at providing the first US dermatology health care needs assessment. This work follows the delineation of the US burden of skin disease and discussion of national clinical dermatology research priorities, while closely following the blueprint set out by the recent dermatology needs assessment of the United Kingdom. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457847</comments>
            <pubDate>Mon, 24 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457847</guid>        </item>
        <item>
            <title>Melanoma: Epidemiology, Diagnosis, Treatment, and Outcomes</title>
            <link>http://www.medworm.com/index.php?rid=5457859&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001422%2Fabstract%3Frss%3Dyes</link>
            <description>Melanoma is a skin cancer that arises from the malignant transformation of melanocytes. Although it is typically considered a pigmented lesion, the clinical presentation of melanoma can vary greatly. With increased efforts in screening and detection of early-stage melanoma, researchers and clinicians hope to improve clinical outcomes for patients with melanoma. Novel immunotherapies directed at specific molecular targets in the pathogenesis of melanoma usher in a new era of treatment of advanced melanoma. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457859</comments>
            <pubDate>Wed, 19 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457859</guid>        </item>
        <item>
            <title>A Review of Health Outcomes in Patients with Psoriasis</title>
            <link>http://www.medworm.com/index.php?rid=5457854&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001483%2Fabstract%3Frss%3Dyes</link>
            <description>The objective of this article is to elucidate the health outcomes of the disease, including its economic and psychosocial burden on the patient. Current treatments options and the economic considerations of treatment costs are reviewed. Psoriasis is a multidimensional disease, so patients benefit from having a multidisciplinary team of dermatologists and other physicians for management of it and of associated comorbid conditions. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457854</comments>
            <pubDate>Wed, 19 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457854</guid>        </item>
        <item>
            <title>Dedication</title>
            <link>http://www.medworm.com/index.php?rid=5457848&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001793%2Fabstract%3Frss%3Dyes</link>
            <description>I dedicate this issue to my mother Mabel C. Dellavalle who died during the production of this issue; I love you and miss you mom. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457848</comments>
            <pubDate>Mon, 26 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457848</guid>        </item>
        <item>
            <title>Index</title>
            <link>http://www.medworm.com/index.php?rid=5237892&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001549%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237892</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:49 +0100</pubDate>
            <guid isPermaLink="false">5237892</guid>        </item>
        <item>
            <title>Treatment of Chronic Bullous Disease of Childhood</title>
            <link>http://www.medworm.com/index.php?rid=5237891&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001616%2Fabstract%3Frss%3Dyes</link>
            <description>This article discusses the management options of CBDC in more detail. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237891</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:49 +0100</pubDate>
            <guid isPermaLink="false">5237891</guid>        </item>
        <item>
            <title>Management of Autoimmune Bullous Diseases in France: A Nationwide Network of 30 Centers</title>
            <link>http://www.medworm.com/index.php?rid=5237883&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001252%2Fabstract%3Frss%3Dyes</link>
            <description>Limited data are available on the epidemiology of autoimmune bullous diseases in France and in Western Europe. Bullous pemphigoid represents the most common autoimmune bullous disease. The management of autoimmune bullous diseases in France is under the guidance of dermatologists. In 1985, a research group focused on autoimmune bullous diseases was created in France. In 2004, the French Ministry of Health established and funded a nationwide network including 2 references centers, 7 competence centers, and 30 corresponding centers, with the aim of improving quality of care and research for autoimmune bullous diseases. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237883</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:49 +0100</pubDate>
            <guid isPermaLink="false">5237883</guid>        </item>
        <item>
            <title>The International Pemphigus and Pemphigoid Foundation</title>
            <link>http://www.medworm.com/index.php?rid=5237882&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001276%2Fabstract%3Frss%3Dyes</link>
            <description>The International Pemphigus Pemphigoid Foundation (IPFF) was founded in 1997. The IPPF lists more than 4500 members. The IPPF provides peer health coaches to aid patients in the navigation of the health care system and recommends dermatologists and other specialists in their area who are experts in autoimmune bullous disease. The IPPF hosts the largest worldwide registry of pemphigus/pemphigoid patients with biospecimen collection opportunities are planned. Twice a year the IPPF hosts formal meetings with invited speakers. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237882</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:49 +0100</pubDate>
            <guid isPermaLink="false">5237882</guid>        </item>
        <item>
            <title>Therapeutic Approaches to Patients with Mucous Membrane Pemphigoid</title>
            <link>http://www.medworm.com/index.php?rid=5237879&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001306%2Fabstract%3Frss%3Dyes</link>
            <description>The therapeutic approach to mucous membrane pemphigoid is site specific, with the goal of preserving function for patients with chronic and treatment-resistant disease. The involvement of certain mucosal sites (ie, ocular, laryngeal, esophageal, nasopharyngeal, and anogenital) is high risk and warrants more aggressive intervention. Control of the disease must be balanced with minimizing the sequelae of long-term exposure to systemic glucocorticosteroids and/or other immunosuppressives. Timely interventions and multidisciplinary management are essential in preventing disability. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237879</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:49 +0100</pubDate>
            <guid isPermaLink="false">5237879</guid>        </item>
        <item>
            <title>Management of Linear IgA Disease</title>
            <link>http://www.medworm.com/index.php?rid=5237877&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001227%2Fabstract%3Frss%3Dyes</link>
            <description>Linear immunoglobulin A (IgA) disease is an acquired autoimmune blistering disease of the skin and mucous membranes that runs a chronic course over 3 to 6 years before remitting. It typically presents with papulovesicles and blisters configured in an arcuate pattern on an urticated base, with 2 peaks of onset. The first peak is in young prepubescent children, called chronic bullous disease of childhood, and the second peak affects patients older than 60 years of age. In this article, the management of linear IgA in adults is considered. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237877</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:49 +0100</pubDate>
            <guid isPermaLink="false">5237877</guid>        </item>
        <item>
            <title>Evidence-Based Treatments in Pemphigus Vulgaris and Pemphigus Foliaceus</title>
            <link>http://www.medworm.com/index.php?rid=5237873&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351100132X%2Fabstract%3Frss%3Dyes</link>
            <description>Treatment modalities in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are many and varied, although level 1 evidence supporting their use is limited. To date, only 2 systematic reviews exist to support the use of different treatment modalities to control this group of conditions. Overall, within the literature, the quality of trials comparing treatment modalities is poor. Cohort sizes are small, methodologies are varied, and standardized outcome measurements are lacking. The authors aim to present a comprehensive view of the level 1 evidence that exists for common treatment modalities used in PV and PF. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237873</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:48 +0100</pubDate>
            <guid isPermaLink="false">5237873</guid>        </item>
        <item>
            <title>Infection and Infection Prevention in Patients Treated with Immunosuppressive Medications for Autoimmune Bullous Disorders</title>
            <link>http://www.medworm.com/index.php?rid=5237872&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351100129X%2Fabstract%3Frss%3Dyes</link>
            <description>Infection contributes to considerable morbidity and mortality in patients treated for autoimmune bullous disorders because of the impaired cutaneous barrier, alteration of the protective normal flora, and host immunosuppression (inherent and iatrogenic). Prevention of cutaneous impetiginization and infection starts with excellent wound care. In patients to be started on immunosuppressive medications, consideration should be given to vaccination status and possible need for pneumocystis pneumonia prevention. Patients should be educated on the signs and symptoms of early infection and the need to seek early medical intervention as needed. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237872</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:48 +0100</pubDate>
            <guid isPermaLink="false">5237872</guid>        </item>
        <item>
            <title>Minimizing Complications in Autoimmune Blistering Diseases</title>
            <link>http://www.medworm.com/index.php?rid=5237870&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001136%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews the supportive management of AIBD and the management of corticosteroid-induced side effects. The prevention and management of secondary effects from some of the more commonly used steroid-sparing agents for AIBD are summarized. Clinicians must be familiar with this information to optimally manage patients with AIBD. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237870</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:48 +0100</pubDate>
            <guid isPermaLink="false">5237870</guid>        </item>
        <item>
            <title>Rituximab and its Use in Autoimmune Bullous Disorders</title>
            <link>http://www.medworm.com/index.php?rid=5237869&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001318%2Fabstract%3Frss%3Dyes</link>
            <description>Rituximab is a chimeric, murine-human, monoclonal antibody against the CD20 antigen of B lymphocytes. It has been used off-label to treat and manage autoimmune and dermatologic diseases as an alternative or adjuvant therapy to systemic treatments. Due to cost, potential complications, and lack of data rituximab is used after standard systemic therapies have failed or the patient is absolutely contraindicated for corticosteroids. More research is required. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237869</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:48 +0100</pubDate>
            <guid isPermaLink="false">5237869</guid>        </item>
        <item>
            <title>Dapsone in the Management of Autoimmune Bullous Diseases</title>
            <link>http://www.medworm.com/index.php?rid=5237867&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001264%2Fabstract%3Frss%3Dyes</link>
            <description>Dapsone is used in the treatment of autoimmune bullous diseases (AIBD), a group of disorders resulting from autoimmunity directed against basement membrane and/or intercellular adhesion molecules on cutaneous and mucosal surfaces. This review summarizes the limited published data evaluating dapsone as a therapy for AIBD. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237867</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:48 +0100</pubDate>
            <guid isPermaLink="false">5237867</guid>        </item>
        <item>
            <title>Azathioprine in the Treatment of Autoimmune Blistering Diseases</title>
            <link>http://www.medworm.com/index.php?rid=5237865&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001173%2Fabstract%3Frss%3Dyes</link>
            <description>Although there are no standard guidelines for the treatment of autoimmune blistering diseases, azathioprine has shown good efficacy in acquired autoimmune blistering diseases, and is well tolerated. Side effects of azathioprine normally occur in mild variants. Severe reactions are due to reduced thiopurine S-methyltransferase (TPMT) or inosine triphosphate pyrophosphohydrolase (ITPA) activity. Therefore, screening for TPMT activity should be conducted in white patients and Africans, whereas Japanese should be screened for ITPA activity before therapy with azathioprine is started. Azathioprine is clinically meaningful for the treatment of pemphigus. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237865</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:48 +0100</pubDate>
            <guid isPermaLink="false">5237865</guid>        </item>
        <item>
            <title>Forthcoming Issues</title>
            <link>http://www.medworm.com/index.php?rid=5237862&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001537%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237862</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:48 +0100</pubDate>
            <guid isPermaLink="false">5237862</guid>        </item>
        <item>
            <title>Contents</title>
            <link>http://www.medworm.com/index.php?rid=5237861&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001525%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237861</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:48 +0100</pubDate>
            <guid isPermaLink="false">5237861</guid>        </item>
        <item>
            <title>Contributors</title>
            <link>http://www.medworm.com/index.php?rid=5237860&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001604%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237860</comments>
            <pubDate>Thu, 22 Sep 2011 07:07:48 +0100</pubDate>
            <guid isPermaLink="false">5237860</guid>        </item>
        <item>
            <title>Autoimmune Blistering Diseases Part II—Diagnosis and Management</title>
            <link>http://www.medworm.com/index.php?rid=5237863&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001367%2Fabstract%3Frss%3Dyes</link>
            <description>When invited to edit a special issue of Dermatologic Clinics on Autoimmune Blistering Diseases by Bruce Thiers, I was delighted and honored to accept. I had just finished editing two issues on the genetic blistering disease, Epidermolysis Bullosa, for Dermatologic Clinics and found that the scientific and dermatologic community were keen to contribute to these theme-based issues. There have been a few excellent textbooks devoted to autoimmune blistering diseases (AIBD), with some focusing on the pathology and others on management, but the field is advancing rapidly. There was so much to cover about AIBD that it was decided to cover clinical features, diagnostic testing, and pathogenesis in the first issue and follow it with this issue on management. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237863</comments>
            <pubDate>Thu, 18 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237863</guid>        </item>
        <item>
            <title>Prevalence and Treatment of Pemphigus in Iran</title>
            <link>http://www.medworm.com/index.php?rid=5237887&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001197%2Fabstract%3Frss%3Dyes</link>
            <description>Autoimmune bullous diseases are a group of diseases caused by autoantibodies against the dermoepidermal junction and desmosome, cleaving the skin and mucous membrane. The clinical forms and the prevalence seem to be different from one continent to another. The prevalence and treatment of pemphigus in Iran are discussed in this article. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237887</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237887</guid>        </item>
        <item>
            <title>Autoimmune Blistering Diseases: Incidence and Treatment in Croatia</title>
            <link>http://www.medworm.com/index.php?rid=5237886&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001343%2Fabstract%3Frss%3Dyes</link>
            <description>Dermatovenereology in Croatia has a long tradition, with the first Department of Dermatovenereology having opened in Zagreb in 1894. The diagnosis of autoimmune bullous disease is based on clinical, histopathologic, and immunopathologic findings. Future goals are to participate in multicenter studies because this is the only possibility for further investigation for these rare diseases. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237886</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237886</guid>        </item>
        <item>
            <title>Management of Epidermolysis Bullosa Acquisita</title>
            <link>http://www.medworm.com/index.php?rid=5237880&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001288%2Fabstract%3Frss%3Dyes</link>
            <description>This article discusses the current management of this disease. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237880</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237880</guid>        </item>
        <item>
            <title>Pemphigoid Gestationis: Current Management</title>
            <link>http://www.medworm.com/index.php?rid=5237876&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001215%2Fabstract%3Frss%3Dyes</link>
            <description>This article discusses the current management of this rare disease. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237876</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237876</guid>        </item>
        <item>
            <title>Current Management Strategies in Paraneoplastic Pemphigus (Paraneoplastic Autoimmune Multiorgan Syndrome)</title>
            <link>http://www.medworm.com/index.php?rid=5237874&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001240%2Fabstract%3Frss%3Dyes</link>
            <description>This article focuses on current management strategies in PNP/PAMS, and reported instances of their treatment successes and failures. Due to the rarity of the condition and the high rates of treatment failure, no randomized control trials exist to guide the evidence-based treatment of this condition; all evidence to date on the efficacy of therapeutic modalities has been gained from individual case reports, small case series, and expert recommendations. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237874</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237874</guid>        </item>
        <item>
            <title>Pemphigus Treatment in Japan</title>
            <link>http://www.medworm.com/index.php?rid=5237888&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001355%2Fabstract%3Frss%3Dyes</link>
            <description>Pemphigus is a group of autoimmune blistering diseases characterized by blisters and erosive lesions on the skin and mucous membranes due to loss of cell and cell adhesion of keratinocytes. In 2010, new Japanese guidelines for the management of pemphigus were published for dermatologists. Systemic corticosteroids are the gold standard and the first choice of treatment of pemphigus. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237888</comments>
            <pubDate>Thu, 11 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237888</guid>        </item>
        <item>
            <title>Management of Autoimmune Blistering Diseases in Spain</title>
            <link>http://www.medworm.com/index.php?rid=5237885&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001148%2Fabstract%3Frss%3Dyes</link>
            <description>This article provides an overview of the management of AIBD in Spain at the present time. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237885</comments>
            <pubDate>Thu, 11 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237885</guid>        </item>
        <item>
            <title>The Autoimmune Blistering Diseases in Australia: Status and Services</title>
            <link>http://www.medworm.com/index.php?rid=5237889&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001331%2Fabstract%3Frss%3Dyes</link>
            <description>This article describes the establishment of a registry and support group to serve patients with these disorders. The registry aids research in Australia by providing epidemiologic data and maintaining an up-to-date database with patient contact details. The support group caters to the needs of patients and/or caregivers. Teledermatology, diagnosis, and management of autoimmune bullous disease are briefly reviewed. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237889</comments>
            <pubDate>Mon, 08 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237889</guid>        </item>
        <item>
            <title>Diagnosis and Treatment of Patients with Autoimmune Bullous Disorders in Germany</title>
            <link>http://www.medworm.com/index.php?rid=5237884&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351100115X%2Fabstract%3Frss%3Dyes</link>
            <description>In Germany, more than 2000 new patients per year have been calculated to be diagnosed with autoimmune blistering diseases. In a recent survey, the most frequently applied treatment regimens for bullous pemphigoid were class IV topical corticosteroids and oral prednisolone 0.5 mg or 1.0 mg/kg/d plus dapsone or azathioprine. For pemphigus, two-thirds of the clinics applied oral prednisolone at doses of 1.0 mg or 1.5 mg/kg/d and in more than 80% of departments, azathioprine was chosen as concomitant immunosuppressant. High-dose intravenous immunoglobulin, rituximab, and immunoadsorption are increasingly used for refractory patients. Treatment and diagnostic costs are covered by the health insurances when applied according to published expert recommendations. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237884</comments>
            <pubDate>Mon, 08 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237884</guid>        </item>
        <item>
            <title>Evidence-Based Management of Bullous Pemphigoid</title>
            <link>http://www.medworm.com/index.php?rid=5237875&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001112%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews the evidence supporting different therapeutic options in the management of BP. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237875</comments>
            <pubDate>Mon, 08 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237875</guid>        </item>
        <item>
            <title>Management of Autoimmune Blistering Diseases in Pregnancy</title>
            <link>http://www.medworm.com/index.php?rid=5237871&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001161%2Fabstract%3Frss%3Dyes</link>
            <description>This article considers the effects of the disease as well as its treatment for both mother and fetus. All AIBDs can occur in pregnancy but are relatively rare. Pemphigoid gestationis is a rare AIBD that is specific to pregnancy. The article considers each AIBD in turn and then looks at treatment options for the group as a whole, as there are many issues common to all. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237871</comments>
            <pubDate>Mon, 08 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237871</guid>        </item>
        <item>
            <title>Mycophenolate Mofetil for the Management of Autoimmune Bullous Diseases</title>
            <link>http://www.medworm.com/index.php?rid=5237866&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001203%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews the use of MMF for the treatment of several bullous conditions, and assesses the evidence gathered from clinical trials and case series. According to numerous case series, MMF could be of value in treating refractory disease. The few randomized clinical trials conducted to date of patients with pemphigus and bullous pemphigoid report a similar efficacy for MMF to other immunosuppressants. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237866</comments>
            <pubDate>Mon, 08 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237866</guid>        </item>
        <item>
            <title>Corticosteroid Use in Autoimmune Blistering Diseases</title>
            <link>http://www.medworm.com/index.php?rid=5237864&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001124%2Fabstract%3Frss%3Dyes</link>
            <description>This article outlines the current level of evidence for corticosteroid use in AIBDs, and discusses appropriate investigations and interventions to minimize or prevent the associated adverse effects. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237864</comments>
            <pubDate>Mon, 08 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237864</guid>        </item>
        <item>
            <title>Bullous Systemic Lupus Erythematosus</title>
            <link>http://www.medworm.com/index.php?rid=5237881&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001100%2Fabstract%3Frss%3Dyes</link>
            <description>Bullous systemic lupus erythematosus (BSLE) is a rare bullous dermatosis in patients with systemic lupus erythematosus. It is characterized by clinical and histologic features, resembling either bullous pemphigoid or dermatitis herpetiformis, and a heterogeneous immunologic profile, characterized by autoimmunity to components of type VII collagen, much like epidermolysis bullosa acquisita. As understanding of the pathology of this interesting dermatologic condition has evolved, so too have criteria and profiling of BSLE. The distinct clinical, histologic, and immunologic features of BSLE represent a unique bullous disease phenotype. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237881</comments>
            <pubDate>Thu, 04 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237881</guid>        </item>
        <item>
            <title>Management of Dermatitis Herpetiformis</title>
            <link>http://www.medworm.com/index.php?rid=5237878&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001239%2Fabstract%3Frss%3Dyes</link>
            <description>The major treatment strategies for DH are gluten restriction or medical treatment with sulfones. Control of the cutaneous manifestations, but not the gastrointestinal changes, is rapid with dapsone. In addition to control of the cutaneous signs and symptoms of DH, dietary gluten restriction also induces improvement of gastrointestinal morphology and is possibly protective against the development of lymphoma. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237878</comments>
            <pubDate>Thu, 04 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237878</guid>        </item>
        <item>
            <title>The Use of Intravenous Immunoglobulin in Autoimmune Bullous Diseases</title>
            <link>http://www.medworm.com/index.php?rid=5237868&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001185%2Fabstract%3Frss%3Dyes</link>
            <description>This article provides an introduction to the make-up and use of IVIG, and reviews previous studies. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237868</comments>
            <pubDate>Thu, 04 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237868</guid>        </item>
        <item>
            <title>Autoimmune Bullous Diseases in Austria</title>
            <link>http://www.medworm.com/index.php?rid=5237890&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511001094%2Fabstract%3Frss%3Dyes</link>
            <description>Autoimmune bullous diseases (AIBD) are chronic disorders associated with significant morbidity and even mortality, for which the 19 dermatologic departments in Austria apply standard modalities to provide state-of-the-art diagnosis and treatment. Most of the affected individuals are initially treated on an inpatient basis, with follow-up done in specialized outpatient clinics or in private practices. A well-established system of care for AIBD patients is thus available nationwide. Considering the significant morbidity and mortality but also rareness of AIBD, national and international standardization of AIBD administration in registries is a major requirement of further improvement in patient care. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5237890</comments>
            <pubDate>Fri, 29 Jul 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5237890</guid>        </item>
        <item>
            <title>Index</title>
            <link>http://www.medworm.com/index.php?rid=4864367&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000866%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864367</comments>
            <pubDate>Thu, 26 May 2011 16:18:59 +0100</pubDate>
            <guid isPermaLink="false">4864367</guid>        </item>
        <item>
            <title>Pemphigus and Quality of Life</title>
            <link>http://www.medworm.com/index.php?rid=4864366&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000428%2Fabstract%3Frss%3Dyes</link>
            <description>Measuring the impact of disease on quality of life (QOL) is important for evaluating effectiveness of care and capturing aspects of health that may not correlate with clinical severity. Few QOL studies have been conducted on pemphigus, and a disease-specific QOL questionnaire for this condition has not been developed. The 5 previous studies of the effect of pemphigus on QOL used generic health or skin-specific measures. These measures have limitations, and results from these studies have sometimes been conflicting. The development of a disease-specific measure for pemphigus would allow for better monitoring of patients' QOL and improve management. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864366</comments>
            <pubDate>Thu, 26 May 2011 16:18:59 +0100</pubDate>
            <guid isPermaLink="false">4864366</guid>        </item>
        <item>
            <title>Objective Scoring Systems for Disease Activity in Autoimmune Bullous Disease</title>
            <link>http://www.medworm.com/index.php?rid=4864365&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000489%2Fabstract%3Frss%3Dyes</link>
            <description>Objectively evaluating disease activity in autoimmune bullous disease (AIBD) is important in terms of the clinical assessment of patients and as an outcome measure for clinical trials. Measures need to be general enough to capture the issues specific to each of the bullous dermatoses but specific enough to capture any changes to disease status for a patient. Different tools have been put forward over the last 15 years, but presently the Autoimmune Bullous Skin Disorder Intensity Score and Pemphigus Disease Area Index seem to be the most promising tools to assess disease activity in AIBD. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864365</comments>
            <pubDate>Thu, 26 May 2011 16:18:59 +0100</pubDate>
            <guid isPermaLink="false">4864365</guid>        </item>
        <item>
            <title>Hair Loss in Autoimmune Cutaneous Bullous Disorders</title>
            <link>http://www.medworm.com/index.php?rid=4864363&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000404%2Fabstract%3Frss%3Dyes</link>
            <description>This article discusses the presence of alopecia in the most common acquired forms of bullous disorders. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864363</comments>
            <pubDate>Thu, 26 May 2011 16:18:59 +0100</pubDate>
            <guid isPermaLink="false">4864363</guid>        </item>
        <item>
            <title>Pathogenesis of Epidermolysis Bullosa Acquisita</title>
            <link>http://www.medworm.com/index.php?rid=4864362&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000258%2Fabstract%3Frss%3Dyes</link>
            <description>Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering skin disease characterized by autoantibodies to type VII collagen. Clinically, a noninflammatory and an inflammatory variant of EBA can be distinguished. Despite major achievements in the understanding of EBA, current therapeutic options are far from optimal. However, with an emerging and more detailed understanding of the events ultimately leading to blister formation in EBA, novel therapeutic options may become available for patients with EBA. Therefore, this article reviews the current understanding of the pathogenesis of EBA and may indicate possible avenues towards a more targeted therapy for EBA and possibly other antibody-mediated autoimmune diseases. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864362</comments>
            <pubDate>Thu, 26 May 2011 16:18:59 +0100</pubDate>
            <guid isPermaLink="false">4864362</guid>        </item>
        <item>
            <title>Diagnosis and Clinical Features of Epidermolysis Bullosa Acquisita</title>
            <link>http://www.medworm.com/index.php?rid=4864361&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000738%2Fabstract%3Frss%3Dyes</link>
            <description>Epidermolysis bullosa acquisita (EBA) is a rare autoimmune subepidermal blistering disease characterized by immune deposits on anchoring fibrils of cutaneous and mucosal basement membrane zones. It is due to circulating antibodies directed to type VII collagen. Clinical manifestations include a classical form with skin fragility, blisters and scars on trauma-prone surfaces, an inflammatory form, and a cicatricial pemphigoid–like form. Specialized tests available in only certain laboratories are necessary to confirm a diagnosis of EBA, such as immunoelectron microscopy, immunoblotting, or ELISA using recombinant proteins. A frequent association between EBA and Crohn disease has been observed. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864361</comments>
            <pubDate>Thu, 26 May 2011 16:18:58 +0100</pubDate>
            <guid isPermaLink="false">4864361</guid>        </item>
        <item>
            <title>Pathogenesis of Mucous Membrane Pemphigoid</title>
            <link>http://www.medworm.com/index.php?rid=4864360&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000441%2Fabstract%3Frss%3Dyes</link>
            <description>Mucous membrane pemphigoid (MMP) is the clinical phenotype of a group of autoimmune blistering diseases characterized by autoantibodies directed against different structural proteins in epidermal basement membranes. The clinical course and prognosis of MMP are affected by the specific autoantigen targeted, the titer and bioactivity profile of corresponding autoantibodies, and the specific mucosal sites of disease activity. Irreversible scarring and loss of function must be prevented by early diagnosis and appropriate interventions. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864360</comments>
            <pubDate>Thu, 26 May 2011 16:18:58 +0100</pubDate>
            <guid isPermaLink="false">4864360</guid>        </item>
        <item>
            <title>Pathophysiology of Dermatitis Herpetiformis: A Model for Cutaneous Manifestations of Gastrointestinal Inflammation</title>
            <link>http://www.medworm.com/index.php?rid=4864359&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000386%2Fabstract%3Frss%3Dyes</link>
            <description>Dermatitis herpetiformis (DH) is an autoimmune blistering skin disease in which antigen presentation in the gastrointestinal mucosa results in cutaneous IgA deposition and distinct, neutrophil-driven cutaneous lesions. Our findings suggest that the qualitatively different immune response to gluten in the intestinal mucosa of patients with DH results in minimal clinical symptoms, allowing the continued ingestion of gluten and the eventual development of DH. Our model may provide a new way to understand the pathogenesis of other skin diseases associated with gastrointestinal inflammation such as pyoderma gangrenosum or erythema nodosum, or explain association of seronegative inflammatory arthritis with inflammatory bowel disease. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864359</comments>
            <pubDate>Thu, 26 May 2011 16:18:58 +0100</pubDate>
            <guid isPermaLink="false">4864359</guid>        </item>
        <item>
            <title>An Exception Within the Group of Autoimmune Blistering Diseases: Dermatitis Herpetiformis, the Gluten-Sensitive Dermopathy</title>
            <link>http://www.medworm.com/index.php?rid=4864358&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000751%2Fabstract%3Frss%3Dyes</link>
            <description>Dermatitis herpetiformis (DH) is characterized by chronic, itching papules, seropapules, small vesicles and, exceptionally, large blisters. The distribution of these polymorphic symptoms around the elbow, knee, buttock, and back is suggestive of the diagnosis. DH is further confirmed by the accumulation of granulocytes at the papillary dermis, resulting in a subepidermal split formation and by the presence of a unique, granular IgA precipitate in the uppermost dermis. Prognosis is predominantly determined by other autoimmune pathologies, malabsorption, or very rarely by lymphomas. Some of these diseases can be prevented by an early-onset, strict gluten-free diet, which is therefore the suggested treatment option. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864358</comments>
            <pubDate>Thu, 26 May 2011 16:18:58 +0100</pubDate>
            <guid isPermaLink="false">4864358</guid>        </item>
        <item>
            <title>Clinical Features, Diagnosis, and Pathogenesis of Chronic Bullous Disease of Childhood</title>
            <link>http://www.medworm.com/index.php?rid=4864357&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000787%2Fabstract%3Frss%3Dyes</link>
            <description>This article discusses the clinical features, diagnosis, and pathogenesis of CBDC in more detail. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864357</comments>
            <pubDate>Thu, 26 May 2011 16:18:58 +0100</pubDate>
            <guid isPermaLink="false">4864357</guid>        </item>
        <item>
            <title>Linear IgA Disease: Clinical Presentation, Diagnosis, and Pathogenesis</title>
            <link>http://www.medworm.com/index.php?rid=4864356&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000465%2Fabstract%3Frss%3Dyes</link>
            <description>Linear IgA disease is one of the rarer subepidermal blistering diseases. Linear IgA disease is a chronic, acquired, autoimmune blistering disease that is characterized by subepidermal blistering and linear deposition of IgA basement membrane antibodies. The disease affects both children and adults and, although there are some differences in their clinical presentations, there is considerable overlap with shared immunopathology and immunogenetics. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864356</comments>
            <pubDate>Thu, 26 May 2011 16:18:58 +0100</pubDate>
            <guid isPermaLink="false">4864356</guid>        </item>
        <item>
            <title>Pemphigoid Gestationis: Pathogenesis and Clinical Features</title>
            <link>http://www.medworm.com/index.php?rid=4864355&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000246%2Fabstract%3Frss%3Dyes</link>
            <description>This article discusses the immunopathogenesis, diagnostic methods, and clinical features of this fascinating disease. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864355</comments>
            <pubDate>Thu, 26 May 2011 16:18:58 +0100</pubDate>
            <guid isPermaLink="false">4864355</guid>        </item>
        <item>
            <title>Pathogenesis of Bullous Pemphigoid</title>
            <link>http://www.medworm.com/index.php?rid=4864354&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000416%2Fabstract%3Frss%3Dyes</link>
            <description>Bullous pemphigoid, the most common autoimmune blistering disease, is induced by autoantibodies against type XVII collagen. Passive transfer of IgG or IgE antibodies against type XVII collagen into animals has revealed not only the pathogenicity of these antibodies but also the subsequent immune responses, including complement activation, mast cell degranulation, and infiltration of neutrophils and/or eosinophils. In vitro studies on ectodomain shedding of type XVII collagen have also provided basic knowledge on the development of bullous pemphigoid. The pathogenic role of autoreactive CD4+ T lymphocytes in the development of the pathogenic autoantibodies to type XVII collagen should also be noted. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864354</comments>
            <pubDate>Thu, 26 May 2011 16:18:58 +0100</pubDate>
            <guid isPermaLink="false">4864354</guid>        </item>
        <item>
            <title>Clinical Features and Practical Diagnosis of Bullous Pemphigoid</title>
            <link>http://www.medworm.com/index.php?rid=4864353&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351100043X%2Fabstract%3Frss%3Dyes</link>
            <description>Bullous pemphigoid (BP) represents the most common autoimmune subepidermal blistering disease. BP typically affects the elderly and is associated with significant morbidity. It has usually a chronic course with spontaneous exacerbations. The cutaneous manifestations of BP can be extremely protean. While diagnosis of BP in the bullous stage is straightforward, in the non-bullous stage or in atypical variants of BP signs and symptoms are frequently non-specific with eg, only itchy excoriated, eczematous, papular and/or urticarial lesions that may persist for several weeks or months. Diagnosis of BP critically relies on immunopathologic examinations including direct immunofluorescence microscopy and detection of serum autoantibodies by indirect immunofluorescence microscopy or BP180-ELISA. (S...</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864353</comments>
            <pubDate>Thu, 26 May 2011 16:18:58 +0100</pubDate>
            <guid isPermaLink="false">4864353</guid>        </item>
        <item>
            <title>Paraneoplastic Pemphigus (Paraneoplastic Autoimmune Multiorgan Syndrome): Clinical Presentations and Pathogenesis</title>
            <link>http://www.medworm.com/index.php?rid=4864352&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351100074X%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews the varied clinical presentations and pathologic characteristics pertaining to paraneoplastic pemphigus. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864352</comments>
            <pubDate>Thu, 26 May 2011 16:18:58 +0100</pubDate>
            <guid isPermaLink="false">4864352</guid>        </item>
        <item>
            <title>Pathogenesis of Endemic Pemphigus Foliaceus</title>
            <link>http://www.medworm.com/index.php?rid=4864351&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000477%2Fabstract%3Frss%3Dyes</link>
            <description>Pemphigus refers to a group of human autoimmune blistering diseases involving skin and/or mucous membranes. Endemic pemphigus foliaceus (EPF), or fogo selvagem is an organ-specific autoimmune blistering disease, first reported in the beginning of the 20th century in rural areas of Brazil. The disease follows the course of streams and creeks, and vanishes after urbanization of the endemic areas. The auto-antigen related to EPF is desmoglein 1, a 160 kDa glycoprotein of the desmossomal core, targeted by in situ and circulating IgG autoantibodies, mainly of the IgG4 subclass. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864351</comments>
            <pubDate>Thu, 26 May 2011 16:18:57 +0100</pubDate>
            <guid isPermaLink="false">4864351</guid>        </item>
        <item>
            <title>Diagnosis and Clinical Features of Pemphigus Foliaceus</title>
            <link>http://www.medworm.com/index.php?rid=4864350&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000453%2Fabstract%3Frss%3Dyes</link>
            <description>This article summarizes the epidemiology, clinical features, techniques for diagnosis, and drugs associated with treatment of this rare disease. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864350</comments>
            <pubDate>Thu, 26 May 2011 16:18:57 +0100</pubDate>
            <guid isPermaLink="false">4864350</guid>        </item>
        <item>
            <title>A Globally Available Internet-Based Patient Survey of Pemphigus Vulgaris: Epidemiology and Disease Characteristics</title>
            <link>http://www.medworm.com/index.php?rid=4864349&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000490%2Fabstract%3Frss%3Dyes</link>
            <description>The authors developed an anonymous, Web-based survey instrument available globally, and collected data from 171 pemphigus vulgaris (PV) patients to assemble epidemiologic data pertaining to an extensive set of clinical parameters in demographically diverse populations. The results showed female predominance, prevalent onset of disease in the fifth decade of life, and a strong correlation of PV with thyroid disease and type 1 diabetes in patients and family members. Most patients have a history of either mucosal-only or mucocutaneous lesions, but numerous patients self-report cutaneous lesions only, without previous or concurrent mucosal lesions, especially in the non–North American PV population. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864349</comments>
            <pubDate>Thu, 26 May 2011 16:18:57 +0100</pubDate>
            <guid isPermaLink="false">4864349</guid>        </item>
        <item>
            <title>The Genetics of Pemphigus</title>
            <link>http://www.medworm.com/index.php?rid=4864348&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000763%2Fabstract%3Frss%3Dyes</link>
            <description>Pemphigus vulgaris (PV) is an autoimmune blistering disorder with a complex etiology involving an interplay of genetic as well as environmental factors, most of which remain unknown. Despite the identification of several human leukocyte antigen (HLA) alleles as risk factors for disease, no other non-HLA genes have clearly been implicated in disease susceptibility. Newer candidate gene and whole-genome approaches are needed to illuminate the full palate of genetic risk elements in PV. Based on this information, genetic-based tools can be expected to provide a scientific rationale for future clinical decision-making by physicians and facilitate an era of personalized medicine. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864348</comments>
            <pubDate>Thu, 26 May 2011 16:18:57 +0100</pubDate>
            <guid isPermaLink="false">4864348</guid>        </item>
        <item>
            <title>Diagnosis and Clinical Features of Pemphigus Vulgaris</title>
            <link>http://www.medworm.com/index.php?rid=4864347&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351100026X%2Fabstract%3Frss%3Dyes</link>
            <description>Autoimmune bullous diseases are associated with autoimmunity against structural components that maintain cell-cell and cell-matrix adhesion in the skin and mucous membranes. They include those where the skin blisters at the basement membrane zone and those where the skin blisters within the epidermis (pemphigus vulgaris, pemphigus foliaceus, and other subtypes of pemphigus). The variants of pemphigus are determined according to the level of intraepidermal split formation. There are 5 main variants of pemphigus: pemphigus vulgaris, pemphigus foliaceus, pemphigus erythematosus, drug-induced pemphigus, and paraneoplastic pemphigus. This review focuses only on pemphigus vulgaris. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864347</comments>
            <pubDate>Thu, 26 May 2011 16:18:57 +0100</pubDate>
            <guid isPermaLink="false">4864347</guid>        </item>
        <item>
            <title>Direct and Indirect Immunofluorescence for the Diagnosis of Bullous Autoimmune Diseases</title>
            <link>http://www.medworm.com/index.php?rid=4864346&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000234%2Fabstract%3Frss%3Dyes</link>
            <description>DIF and IIF evaluates in vivo bound and circulating autoantibodies and are the preferred methods for diagnosing AIBDs. In pemphigus diseases and dermatitis herpetiformis, the titer of circulating autoantibodies reflects the disease activity. In patients with a classical clinical picture, the DIF confirms the diagnosis. Furthermore, this technique is essential in subtypes of AIBDs with atypical clinical manifestations (eg, no blisters or erosions) or clinically similar presenting manifestations, such as bullous pemphigoid, MMP, or EBA. A direct or indirect SSST is often crucial for the differential diagnosis between subtypes of these diseases, leading to proper treatment for severely affected patients. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864346</comments>
            <pubDate>Thu, 26 May 2011 16:18:57 +0100</pubDate>
            <guid isPermaLink="false">4864346</guid>        </item>
        <item>
            <title>Preface: Autoimmune Blistering Diseases: Part I - Pathogenesis and Clinical Features</title>
            <link>http://www.medworm.com/index.php?rid=4864345&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000775%2Fabstract%3Frss%3Dyes</link>
            <description>When invited to edit a special issue of Dermatologic Clinics on Autoimmune Blistering Diseases by Bruce Thiers, I was delighted and honored to accept.  There have been very few textbooks devoted to autoimmune blistering diseases (AIBD), with some focusing on the pathology and others on management. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864345</comments>
            <pubDate>Thu, 26 May 2011 16:18:57 +0100</pubDate>
            <guid isPermaLink="false">4864345</guid>        </item>
        <item>
            <title>Forthcoming Issues</title>
            <link>http://www.medworm.com/index.php?rid=4864344&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000854%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864344</comments>
            <pubDate>Thu, 26 May 2011 16:18:57 +0100</pubDate>
            <guid isPermaLink="false">4864344</guid>        </item>
        <item>
            <title>Contents</title>
            <link>http://www.medworm.com/index.php?rid=4864343&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000842%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864343</comments>
            <pubDate>Thu, 26 May 2011 16:18:57 +0100</pubDate>
            <guid isPermaLink="false">4864343</guid>        </item>
        <item>
            <title>Contributors</title>
            <link>http://www.medworm.com/index.php?rid=4864342&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000830%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864342</comments>
            <pubDate>Thu, 26 May 2011 16:18:57 +0100</pubDate>
            <guid isPermaLink="false">4864342</guid>        </item>
        <item>
            <title>Nail Involvement in Autoimmune Bullous Disorders</title>
            <link>http://www.medworm.com/index.php?rid=4864364&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000398%2Fabstract%3Frss%3Dyes</link>
            <description>Autoimmune bullous disorders frequently cause nail abnormalities, particularly paronychia and onychomadesis. In pemphigus vulgaris (PV) nail abnormalities can even precede skin findings. Nail lesions often relapse just before generalized disease exacerbation or recurrence. Severe nail changes are often associated with extensive and severe disease. Fingernails are more commonly affected. A report in the literature associates hemorrhagic nail abnormalities with poor prognosis in patients with PV. Nail scarring and pterygium are a rare complication of bullous pemphigoid. Nail loss has been occasionally reported in epidermolysis bullosa acquisita. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4864364</comments>
            <pubDate>Thu, 28 Apr 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4864364</guid>        </item>
        <item>
            <title>Index</title>
            <link>http://www.medworm.com/index.php?rid=4644733&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000349%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644733</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:24 +0100</pubDate>
            <guid isPermaLink="false">4644733</guid>        </item>
        <item>
            <title>Current Procedural Terminology Coding for Mohs Micrographic Surgery</title>
            <link>http://www.medworm.com/index.php?rid=4644732&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351100009X%2Fabstract%3Frss%3Dyes</link>
            <description>Accurate surgical current procedural terminology (CPT) coding allows for proper reimbursement, decreases the possibility of being audited, and decreases the likelihood of inadvertently misrepresenting a claim. The CPT codes describe the type of services provided to a patient. CPT modifiers provide information to insurance payers to assure that the provider is reimbursed correctly. When coding for reconstruction of a surgical defect, the appropriate code is determined by the type of reconstruction performed. Reconstructive procedures that are performed because of underlying tumors are reimbursed. Adequate documentation is essential, because this substantiates claims and promotes their timely processing. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644732</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:24 +0100</pubDate>
            <guid isPermaLink="false">4644732</guid>        </item>
        <item>
            <title>Setting up the Mohs Surgery Laboratory</title>
            <link>http://www.medworm.com/index.php?rid=4644731&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000088%2Fabstract%3Frss%3Dyes</link>
            <description>Mohs micrographic surgery has the highest cure rate for skin cancer. Accurate and precise preparation of horizontal frozen sections in the laboratory is essential for the success of Mohs micrographic surgery. Key considerations in developing the Mohs surgery laboratory are careful planning and design, selection of proper equipment and supplies, training of laboratory personnel, adherence to regulatory standards of Clinical Laboratory Improvement Amendments (CLIA), and execution of an effective daily routine. The method of tissue processing used in the laboratory must yield optimal results for processing skin in an efficient manner. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644731</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:24 +0100</pubDate>
            <guid isPermaLink="false">4644731</guid>        </item>
        <item>
            <title>Prosthetic Rehabilitation</title>
            <link>http://www.medworm.com/index.php?rid=4644730&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000076%2Fabstract%3Frss%3Dyes</link>
            <description>Patients with head and neck defects may undergo reconstruction surgically, prosthetically, or with a combined approach. In some situations, prosthetic rehabilitation may be the preferred treatment option. Presurgical treatment planning and evaluation of the patient is paramount to successful reconstruction and rehabilitation. Patient education and assessment of the patient’s expectations are essential in the acceptance of a proposed treatment plan. Communication and joint treatment planning early in the process between the surgeon and maxillofacial prosthodontist will optimize results. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644730</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:24 +0100</pubDate>
            <guid isPermaLink="false">4644730</guid>        </item>
        <item>
            <title>Multidisciplinary Approach to Large Cutaneous Tumors of the Head and Neck</title>
            <link>http://www.medworm.com/index.php?rid=4644729&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000143%2Fabstract%3Frss%3Dyes</link>
            <description>Large cutaneous tumors of the head and neck provide challenges for complete excision and optimal reconstruction. Collaborative intraoperative Mohs micrographic surgery offers efficient and reliable extirpation of large cutaneous malignancies of the head and neck and immediate reconstruction of resultant defects. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644729</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:24 +0100</pubDate>
            <guid isPermaLink="false">4644729</guid>        </item>
        <item>
            <title>Special Considerations for Mohs Micrographic Surgery on the Eyelids, Lips, Genitalia, and Nail Unit</title>
            <link>http://www.medworm.com/index.php?rid=4644728&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000064%2Fabstract%3Frss%3Dyes</link>
            <description>Although skin cancers on the eyelids, lips, genitalia, and the nail unit are infrequent, some skin cancers can have higher recurrence rates in these anatomic locations. Intrinsic to Mohs micrographic surgery (MMS) is maximal tissue preservation and high cure rates, making it a worthwhile procedure for these sensitive anatomic areas to ameliorate any functional or aesthetic compromise. The Mohs surgeon can provide a great service to patients by being aware of the anatomy, specialized instruments, unique histology, and potential complications when performing MMS on these areas. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644728</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:24 +0100</pubDate>
            <guid isPermaLink="false">4644728</guid>        </item>
        <item>
            <title>Nonsurgical Treatment of Nonmelanoma Skin Cancer</title>
            <link>http://www.medworm.com/index.php?rid=4644727&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351100012X%2Fabstract%3Frss%3Dyes</link>
            <description>This article explores the available nonsurgical treatment options, their indications, and their efficacy. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644727</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:24 +0100</pubDate>
            <guid isPermaLink="false">4644727</guid>        </item>
        <item>
            <title>The Role of Radiation Therapy in the Management of Skin Cancers</title>
            <link>http://www.medworm.com/index.php?rid=4644726&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000052%2Fabstract%3Frss%3Dyes</link>
            <description>The use of radiation therapy in the management of skin cancer is variable and often anecdotal. Applied as both primary and adjuvant therapy in patients with both nonmelanoma skin cancer and rarer tumors of the skin, a consensus regarding optimal dosing regimens has not yet been reached. Herein, the authors outline the basic concepts of radiation therapy for tumors of the skin and review its use for high-risk nonmelanoma skin cancer, as well as less common malignancies, including angiosarcoma, Merkel cell carcinoma, and sebaceous carcinoma. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644726</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:24 +0100</pubDate>
            <guid isPermaLink="false">4644726</guid>        </item>
        <item>
            <title>Special Stains in Mohs Surgery</title>
            <link>http://www.medworm.com/index.php?rid=4644725&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000040%2Fabstract%3Frss%3Dyes</link>
            <description>This article focuses on practical aspects involving the most commonly used immunostains in dermatologic surgery, including MART-1 for melanocytic neoplasms, cytokeratin stains for keratinocytic neoplasms, and CD34 stains for dermatofibrosarcoma protuberans. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644725</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:24 +0100</pubDate>
            <guid isPermaLink="false">4644725</guid>        </item>
        <item>
            <title>Histologic Pitfalls in the Mohs Technique</title>
            <link>http://www.medworm.com/index.php?rid=4644724&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000039%2Fabstract%3Frss%3Dyes</link>
            <description>The success of the Mohs procedure depends on the reliability of each step in the technique. Pitfalls in histologic preparation of the tissue specimens may occur during debulking, excising, orienting, creating the map, sectioning, inking, tissue flattening and freezing, cutting, slide fixation, staining, and mapping the tumor. Challenges are also present in interpreting the slides. Diagnostic pitfalls include floaters, inflammatory conditions resembling tumor, and perineural invasion. The technique requires time, teaching, and a sufficient quantity of cases from which to learn, as well as attention to the pitfalls that occur while processing tissue specimens and interpreting and mapping the histology. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644724</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:24 +0100</pubDate>
            <guid isPermaLink="false">4644724</guid>        </item>
        <item>
            <title>Imaging in Cutaneous Oncology: Radiology for Dermies</title>
            <link>http://www.medworm.com/index.php?rid=4644723&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000106%2Fabstract%3Frss%3Dyes</link>
            <description>An overview of currently available imaging modalities is presented. Indications for imaging in cutaneous nonmelanoma skin cancers, selection of the most appropriate and cost-effective study, limitations, and risks are discussed. Finally, representative cases are discussed with emphasis on choice of imaging study for preoperative staging and treatment planning. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644723</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:24 +0100</pubDate>
            <guid isPermaLink="false">4644723</guid>        </item>
        <item>
            <title>Management of Skin Cancer in Solid-organ Transplant Recipients: A Multidisciplinary Approach</title>
            <link>http://www.medworm.com/index.php?rid=4644722&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000179%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews the problem of skin cancer in solid-organ transplant recipients, outlines preventive measures, discusses therapeutic modalities, and reinforces the advantage of a multidisciplinary approach in the management of this population. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644722</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644722</guid>        </item>
        <item>
            <title>Flaps and Grafts Reconstruction</title>
            <link>http://www.medworm.com/index.php?rid=4644721&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000210%2Fabstract%3Frss%3Dyes</link>
            <description>This article discusses in detail the use of local skin flaps and graft reconstruction. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644721</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644721</guid>        </item>
        <item>
            <title>Management of Unusual Cutaneous Malignancies: Atypical Fibroxanthoma, Malignant Fibrous Histiocytoma, Sebaceous Carcinoma, Extramammary Paget Disease</title>
            <link>http://www.medworm.com/index.php?rid=4644720&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000209%2Fabstract%3Frss%3Dyes</link>
            <description>Atypical fibroxanthoma, malignant fibrous histiocytoma, sebaceous carcinoma, and extramammary Paget disease are rare cutaneous tumors. Their recognition and diagnosis are critical in decreasing long-term morbidity and mortality. Surgical excision is the treatment of choice for these tumors, and Mohs micrographic surgery has been shown to be as favorable or better than wide local excision in providing long-term clearance rates. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644720</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644720</guid>        </item>
        <item>
            <title>Advances in Management of Dermatofibrosarcoma Protuberans</title>
            <link>http://www.medworm.com/index.php?rid=4644719&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000167%2Fabstract%3Frss%3Dyes</link>
            <description>Dermatofibrosarcoma protuberans (DFSP) is a rare soft-tissue tumor that most commonly presents on the trunk and extremities of adults. It is characterized by low metastatic potential and a favorable prognosis, but extensive subclinical growth can contribute to a high risk of local recurrence. Surgical excision is the first-line treatment, using Mohs micrographic surgery or wide local excision with careful evaluation of the peripheral and deep surgical margins. Adjuvant therapy may be beneficial in patients with unresectable, recurrent, or metastatic DFSP. Historically, adjuvant radiation therapy has been used to reduce the risk of local recurrence when residual disease is present after surgery. The advent of targeted molecular therapies, such as the selective tyrosine kinase inhibitor, ima...</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644719</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644719</guid>        </item>
        <item>
            <title>Mohs Micrographic Surgery in the Treatment of Microcystic Adnexal Carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=4644718&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000131%2Fabstract%3Frss%3Dyes</link>
            <description>Microcystic adnexal carcinoma is a rare neoplasm with a propensity for slow growth and extensive local invasion. Pathology is characterized by multiple islands of basaloid epithelial cells, ductal structures, and keratinizing cysts, located intradermally but often extending deep as thin strands of tumor cells intercalating between collagen bundles. Perineural and intramuscular invasion are common. Treatment with Mohs surgery allows for fewer procedures with increased likelihood of long-term cure and tissue conservation. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644718</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644718</guid>        </item>
        <item>
            <title>Mohs Surgery for Melanoma in Situ</title>
            <link>http://www.medworm.com/index.php?rid=4644717&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000027%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews the different variations of Mohs micrographic surgery that are currently used for melanoma in situ. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644717</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644717</guid>        </item>
        <item>
            <title>Mohs Surgery for Squamous Cell Carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=4644716&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000192%2Fabstract%3Frss%3Dyes</link>
            <description>Cutaneous squamous cell carcinoma (SCC) is the second most common human cancer and can behave aggressively. Mohs micrographic surgery offers the highest cure rates for high-risk SCCs and is particularly useful for SCCs on challenging anatomic sites. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644716</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644716</guid>        </item>
        <item>
            <title>An Overview of Mohs Micrographic Surgery for the Treatment of Basal Cell Carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=4644715&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000180%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews Mohs micrographic surgery for basal cell carcinoma. Its evolution to the present day technique, indications, and limitations are discussed, along with future expectations for the procedure. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644715</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644715</guid>        </item>
        <item>
            <title>Mohs Micrographic Surgery Technique</title>
            <link>http://www.medworm.com/index.php?rid=4644714&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000155%2Fabstract%3Frss%3Dyes</link>
            <description>This article provides a protocol for the systematic approach to the technique of Mohs micrographic surgery. Each step, from tumor excision and tissue mapping, to specimen processing and histologic interpretation, through wound closure and postoperative management, is covered. The advantages of Mohs surgery over other treatment modalities are observed histologic margin control, superior cure rates, and maximal tissue-sparing potential. The increased preservation of normal tissue leads to smaller surgical defects, optimal reconstructive results, and diminished risk of poor surgical outcomes. Overall, the risks of the procedure are few, the benefits numerous, and the outcomes worth the time and effort spent in learning the technique. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644714</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644714</guid>        </item>
        <item>
            <title>History of Mohs Surgery</title>
            <link>http://www.medworm.com/index.php?rid=4644713&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000118%2Fabstract%3Frss%3Dyes</link>
            <description>Mohs micrographic surgery (MMS) has become the gold standard for treating many forms of primary and recurrent contiguous skin cancers and offers the highest cure rates and maximum tissue conservation compared with other modalities. Developed by Dr Frederic E. Mohs in the 1930s, it was initially called chemosurgery and used zinc chloride paste in a process called fixed tissue technique. Although this technique had high cure rates, it could take days to complete, and it gradually gave way to fresh tissue technique, renamed MMS. Now, MMS is practiced widely as part of a multidisciplinary approach for treating skin cancer. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644713</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644713</guid>        </item>
        <item>
            <title>Preface</title>
            <link>http://www.medworm.com/index.php?rid=4644712&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000222%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644712</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644712</guid>        </item>
        <item>
            <title>Forthcoming Issues</title>
            <link>http://www.medworm.com/index.php?rid=4644711&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000337%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644711</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644711</guid>        </item>
        <item>
            <title>Contents</title>
            <link>http://www.medworm.com/index.php?rid=4644710&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000325%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644710</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644710</guid>        </item>
        <item>
            <title>Contributors</title>
            <link>http://www.medworm.com/index.php?rid=4644709&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863511000313%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4644709</comments>
            <pubDate>Tue, 29 Mar 2011 15:51:23 +0100</pubDate>
            <guid isPermaLink="false">4644709</guid>        </item>
        <item>
            <title>Index</title>
            <link>http://www.medworm.com/index.php?rid=4191985&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001919%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191985</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:17 +0100</pubDate>
            <guid isPermaLink="false">4191985</guid>        </item>
        <item>
            <title>Human Immunodeficiency Virus and Leprosy: An Update</title>
            <link>http://www.medworm.com/index.php?rid=4191984&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001415%2Fabstract%3Frss%3Dyes</link>
            <description>Coinfection with human immunodeficiency virus (HIV) has a major effect on the natural history of many infectious diseases, particularly mycobacterial diseases. Early in the HIV epidemic, it was predicted that HIV infection would worsen leprosy outcomes, with more patients developing lepromatous disease, an impaired response to multidrug therapy and fewer reactions. However, studies on the epidemiologic and clinical aspects of leprosy suggest that the course of leprosy in coinfected patients has not been greatly altered by HIV. In contrast, initiation of antiretroviral treatment has been reported to be associated with activation of subclinical Mycobacterium leprae infection and exacerbation of existing leprosy lesions. With regular new discoveries about the interaction of leprosy and HIV, t...</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191984</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:17 +0100</pubDate>
            <guid isPermaLink="false">4191984</guid>        </item>
        <item>
            <title>Female Genital Mutilation: What Every American Dermatologist Needs to Know</title>
            <link>http://www.medworm.com/index.php?rid=4191982&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001439%2Fabstract%3Frss%3Dyes</link>
            <description>Female genital mutilation (FGM) has become more common in the United States with increased immigration to the United States of individuals from areas where the practice is endemic. Although the root causes of FGM may be multiple, the practice is banned in the United States on all women under age 18 and is increasingly being outlawed by individual state legislatures. American dermatologists should expect to see a growing number of patients having undergone FGM who may present with complications ranging from keloids and epidermal cysts to clitoral neuromas and abscess formation. While treatment of such complications is often elusive and unsuccessful, recognition of the practice may prevent future patient abuse and death. The eradication of FGM will require the concerted efforts of many indi...</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191982</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:16 +0100</pubDate>
            <guid isPermaLink="false">4191982</guid>        </item>
        <item>
            <title>Innate Immunity and Leishmania Vaccination Strategies</title>
            <link>http://www.medworm.com/index.php?rid=4191981&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001397%2Fabstract%3Frss%3Dyes</link>
            <description>Despite the ubiquity and severity of parasitic diseases and our desire to prevent them, there are no effective antiparasitic vaccines in widespread clinical use. This review focuses on strategies for development of a vaccine against cutaneous leishmaniasis as a representative parasitic disease of paramount interest to dermatologists and all who care for patients who live in or travel to the developing world. Any effective strategy will require attention to the central role that host innate immunity plays during induction of durable resistance to these virulent protozoa. The cell types, receptors, and molecules of the innate immune system that will likely play a role in any effective vaccine against cutaneous leishmaniasis are reviewed. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191981</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:15 +0100</pubDate>
            <guid isPermaLink="false">4191981</guid>        </item>
        <item>
            <title>Albinism in Africa: Stigma, Slaughter and Awareness Campaigns</title>
            <link>http://www.medworm.com/index.php?rid=4191980&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001403%2Fabstract%3Frss%3Dyes</link>
            <description>Oculocutaneous albinism is an autosomal recessive disorder characterized by a lack of pigment in the hair, skin, and eyes. Albinism is caused by defective or absent tyrosinase, an enzyme necessary for melanogenesis. Although rare in the western world, albinism is quite common in sub-Saharan Africa, likely as a result of consanguinity. Albinism has long been associated with stigma and superstitions, such as the belief that a white man impregnated the mother or that the child is the ghost of a European colonist. Recently, a notion has emerged that albino body parts are good-luck charms or possess magical powers. These body parts may be sold for as much as $75,000 on the black market. As a result there have been over 100 albino murders in Tanzania, Burundi, and other parts of Africa in the pa...</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191980</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:15 +0100</pubDate>
            <guid isPermaLink="false">4191980</guid>        </item>
        <item>
            <title>Cutaneous Leishmaniasis in Mali</title>
            <link>http://www.medworm.com/index.php?rid=4191979&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001385%2Fabstract%3Frss%3Dyes</link>
            <description>This article focuses on cutaneous leishmaniasis in Mali, West Africa. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191979</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:15 +0100</pubDate>
            <guid isPermaLink="false">4191979</guid>        </item>
        <item>
            <title>Effectiveness of Gentian Violet and Similar Products Commonly Used to Treat Pyodermas</title>
            <link>http://www.medworm.com/index.php?rid=4191978&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001348%2Fabstract%3Frss%3Dyes</link>
            <description>The term pyoderma encompasses a variety of distinct entities including impetigo (bullous and nonbullous), erysipelas, cellulitis, folliculitis, and staphylococcal scalded skin syndrome. Treatment of pyodermas centers around wound care and appropriate antibiotic selection. Triphenylmethane dyes, such as gentian violet, represent a unique group of compounds that act as antiseptics and have shown clinical efficacy as antibiotics in a variety of pyodermas, including those secondary to methicillin-resistant Staphylococcus aureus. Given their low cost, ease of application, and favorable side effect profile, triphenylmethanes must be considered legitimate treatment options for pyodermas, particularly in the face of continued and emerging bacterial resistance. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191978</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:14 +0100</pubDate>
            <guid isPermaLink="false">4191978</guid>        </item>
        <item>
            <title>Dermatology in Botswana: The American Academy of Dermatology’s Resident International Grant</title>
            <link>http://www.medworm.com/index.php?rid=4191977&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001427%2Fabstract%3Frss%3Dyes</link>
            <description>In 2008, the American Academy of Dermatology began sponsoring North American dermatology residents to travel to Botswana in sub-Saharan Africa and spend 4 to 6 weeks working with the Botswana-UPenn Partnership, the Baylor International Pediatrics AIDS Initiative, Princess Marina Hospital, and surrounding smaller district hospitals. During their time in Botswana, the residents staff the busy outpatient dermatology clinic and see adult and pediatric inpatients at Princess Marina Hospital in Gaborone, the capital city. The residents also travel to 4 rural hospitals to provide clinical services to patient and education to local health care providers. The program goals include providing direct care to the people of Botswana, capacity-building through dermatologic education for local clinicians,...</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191977</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:14 +0100</pubDate>
            <guid isPermaLink="false">4191977</guid>        </item>
        <item>
            <title>Chagas Disease: Coming to a Place Near You</title>
            <link>http://www.medworm.com/index.php?rid=4191976&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001361%2Fabstract%3Frss%3Dyes</link>
            <description>This article discusses the mode of transmission, evolving epidemiology, pathogenesis, diagnosis, treatment and prevention and control of the disease. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191976</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:14 +0100</pubDate>
            <guid isPermaLink="false">4191976</guid>        </item>
        <item>
            <title>Arsenical Keratoses in Bangladesh—Update and Prevention Strategies</title>
            <link>http://www.medworm.com/index.php?rid=4191975&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001440%2Fabstract%3Frss%3Dyes</link>
            <description>Arsenic is considered a Class I human carcinogen by the International Agency for Research on Cancer because of its increased risk for skin cancer, as well as internal cancers, such as lung and bladder cancer. Arsenic contamination of drinking water in Bangladesh has been called the “largest mass poisoning of a population in history.” This inorganic arsenic contamination is of natural origin, with arsenic thought to be released to the groundwater from the surrounding sediment. Arsenicosis and its risk factors and prevention and management are discussed in this article. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191975</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:13 +0100</pubDate>
            <guid isPermaLink="false">4191975</guid>        </item>
        <item>
            <title>Immune Reconstitution Inflammatory Syndrome and Tropical Dermatoses</title>
            <link>http://www.medworm.com/index.php?rid=4191974&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001798%2Fabstract%3Frss%3Dyes</link>
            <description>This article explores the range of tropical dermatoses that are reported to date with associated IRIS events. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191974</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:13 +0100</pubDate>
            <guid isPermaLink="false">4191974</guid>        </item>
        <item>
            <title>Mosquito-Borne Hemorrhagic Fevers</title>
            <link>http://www.medworm.com/index.php?rid=4191973&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001816%2Fabstract%3Frss%3Dyes</link>
            <description>This article highlights these diseases, with particular focus on dengue, yellow fever, and viral hemorrhagic fever. A general background is provided, as well information concerning diagnosis and treatment. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191973</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:13 +0100</pubDate>
            <guid isPermaLink="false">4191973</guid>        </item>
        <item>
            <title>Community-associated Methicillin-resistant Staphylococcus aureus Skin Infections in the Tropics</title>
            <link>http://www.medworm.com/index.php?rid=4191972&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001774%2Fabstract%3Frss%3Dyes</link>
            <description>Skin and soft tissue infections (SSTI) caused by Staphylococcus aureus are very common, particularly in children, in tropical regions. The proportion of S aureus SSTI caused by community-associated methicillin-resistant S aureus (CA-MRSA) varies according to region, but is up to 25% in some areas. There are diverse CA-MRSA clones, including several that harbor Panton-Valentine leukocidin. Key predisposing factors for staphylococcal infections are scabies infestation, overcrowding, poor hygiene, and inadequate water supplies. In the setting of a community outbreak of staphylococcal SSTI, interventions intended to improve personal and community hygiene are likely to be the most practical, effective, and achievable. Options for oral treatment of clinical infections caused by CA-MRSA include c...</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191972</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:12 +0100</pubDate>
            <guid isPermaLink="false">4191972</guid>        </item>
        <item>
            <title>Dermatology Aboard the USNS COMFORT: Disaster Relief Operations in Haiti After the 2010 Earthquake</title>
            <link>http://www.medworm.com/index.php?rid=4191971&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001579%2Fabstract%3Frss%3Dyes</link>
            <description>On the 12th of January 2010, Haiti was struck by a 7.0 Richter magnitude earthquake that devastated its already fragile capital region. Approximately 230,000 people died immediately or during ensuing weeks, mostly due to acute trauma. Countless others suffered significant life- or limb-threatening injuries. As a part of the United States' response to this tragedy, eventually named Operation Unified Response, the United States Navy deployed hundreds of physicians and other medical response individuals on a hospital ship. Operation Unified Response was a military joint task force operation augmented by governmental and nongovernmental organizations. Its mission was to bring medical and logistical support to the region. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191971</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:12 +0100</pubDate>
            <guid isPermaLink="false">4191971</guid>        </item>
        <item>
            <title>Outbreak of Nontuberculous Mycobacterial Disease in the Central Pacific</title>
            <link>http://www.medworm.com/index.php?rid=4191970&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001804%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews the fascinating history of this skin disease on Satowan, its distinctive clinical presentation, and recommendations for diagnosis and treatment of clinically similar skin lesions in Pacific Islanders. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191970</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:12 +0100</pubDate>
            <guid isPermaLink="false">4191970</guid>        </item>
        <item>
            <title>Buruli Ulcer: Advances in Understanding Mycobacterium ulcerans Infection</title>
            <link>http://www.medworm.com/index.php?rid=4191969&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001786%2Fabstract%3Frss%3Dyes</link>
            <description>Buruli ulcer (BU), caused by the environmental organism Mycobacterium ulcerans and characterized by necrotizing skin and bone lesions, poses important public health issues as the third most common mycobacterial infection in humans. Pathogenesis of M ulcerans is mediated by mycolactone, a necrotizing immunosuppressive toxin. First-line therapy for BU is rifampin plus streptomycin, sometimes with surgery. New insights into the pathogenesis of BU should improve control strategies. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191969</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:11 +0100</pubDate>
            <guid isPermaLink="false">4191969</guid>        </item>
        <item>
            <title>Preface: Special Topics in Tropical Dermatology</title>
            <link>http://www.medworm.com/index.php?rid=4191968&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351000183X%2Fabstract%3Frss%3Dyes</link>
            <description>Thank you for pausing to read this introduction. This is not your typical publication on Tropical Dermatology. This is something new. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191968</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:11 +0100</pubDate>
            <guid isPermaLink="false">4191968</guid>        </item>
        <item>
            <title>Forthcoming Issues</title>
            <link>http://www.medworm.com/index.php?rid=4191967&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001907%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191967</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:11 +0100</pubDate>
            <guid isPermaLink="false">4191967</guid>        </item>
        <item>
            <title>Contents</title>
            <link>http://www.medworm.com/index.php?rid=4191966&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001890%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191966</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:11 +0100</pubDate>
            <guid isPermaLink="false">4191966</guid>        </item>
        <item>
            <title>Contributors</title>
            <link>http://www.medworm.com/index.php?rid=4191965&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001889%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191965</comments>
            <pubDate>Wed, 24 Nov 2010 04:18:11 +0100</pubDate>
            <guid isPermaLink="false">4191965</guid>        </item>
        <item>
            <title>Widespread Use of Toxic Skin Lightening Compounds: Medical and Psychosocial Aspects</title>
            <link>http://www.medworm.com/index.php?rid=4191983&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351000135X%2Fabstract%3Frss%3Dyes</link>
            <description>Hyperpigmentation disorders and skin lightening treatments have a significant impact on the dermatologic, physiologic, psychologic, economic, social, and cultural aspects of life. Skin lightening compounds, such as hydroquinone and topical corticosteroids, are often used to treat hyperpigmentation disorders, such as melasma, or lighten skin for cosmetic purposes. Despite their established effectiveness, a multitude of dermatologic and systemic complications have been associated with these agents. Regulatory agencies have also recognized the adverse effects of skin lighteners and many countries around the world now forbid the production and sale of these compounds, although this prohibition has not significantly curtailed distribution. Dermatologists and users of cosmetic products should be...</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4191983</comments>
            <pubDate>Thu, 14 Oct 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">4191983</guid>        </item>
        <item>
            <title>Index</title>
            <link>http://www.medworm.com/index.php?rid=4019456&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS073386351000152X%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4019456</comments>
            <pubDate>Thu, 30 Sep 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4019456</guid>        </item>
        <item>
            <title>Extramammary Paget’s Disease: Summary of Current Knowledge</title>
            <link>http://www.medworm.com/index.php?rid=4019455&amp;cid=s_33221_12_f&amp;fid=33221&amp;url=http%3A%2F%2Fwww.derm.theclinics.com%2Farticle%2FPIIS0733863510001270%2Fabstract%3Frss%3Dyes</link>
            <description>This article also provides a practical approach to patients with EMPD. (Source: Dermatologic Clinics)</description>
            <author>Dermatologic Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4019455</comments>
            <pubDate>Thu, 30 Sep 2010 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4019455</guid>        </item>
    </channel>
</rss>

